Array
(
    [ID] => 159
    [IBLOCK_ID] => 6
    [NAME] => Основное описание
    [ACTIVE] => Y
    [SORT] => 500
    [CODE] => CONTENT
    [DEFAULT_VALUE] => Array
        (
            [TEXT] => 
            [TYPE] => HTML
        )

    [PROPERTY_TYPE] => S
    [ROW_COUNT] => 1
    [COL_COUNT] => 30
    [LIST_TYPE] => L
    [MULTIPLE] => N
    [XML_ID] => 
    [FILE_TYPE] => 
    [MULTIPLE_CNT] => 5
    [LINK_IBLOCK_ID] => 0
    [WITH_DESCRIPTION] => N
    [SEARCHABLE] => N
    [FILTRABLE] => N
    [IS_REQUIRED] => N
    [VERSION] => 1
    [USER_TYPE] => HTML
    [USER_TYPE_SETTINGS] => Array
        (
            [height] => 200
        )

    [HINT] => 
    [~NAME] => Основное описание
    [~DEFAULT_VALUE] => Array
        (
            [TEXT] => 
            [TYPE] => HTML
        )

    [VALUE_ENUM] => 
    [VALUE_XML_ID] => 
    [VALUE_SORT] => 
    [VALUE] => 
    [PROPERTY_VALUE_ID] => 
    [DESCRIPTION] => 
    [~DESCRIPTION] => 
    [~VALUE] => 
)
  

	Скрининг рисков врожденной и наследственной патологии плода (трисомия 21 - синдром Дауна, трисомия 18 - синдром Эдвардса, трисомия 13 хромосомы - синдром Патау) на сроке 8-14 недель, с помощью программы ASTRAIA, разработанной Фондом Медицины Плода (Fetal Medicine Foundation – FMF).